Skip to main content Help with accessibility Skip to main navigation

Upadacitinib

Indication

Treating moderate to severe atopic dermatitis - NICE TA814

NICE TA814 - Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis

MHRA Drug Safety Update, 26 April 2023

JAK Inhibitors MHRA Drug Safety Update

Red

Brand:

Nice TA:

814

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Skin

Background

1.1 Abrocitinib and upadacitinib are recommended as options for treating moderate to severe atopic dermatitis that is suitable for systemic treatment in adults and young people 12 years and over, only if:

  • the disease has not responded to at least 1 systemic immunosuppressant, or these are not suitable

  • the companies provide abrocitinib and upadacitinib according to the commercial arrangement.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD
BP
CSR
EL
FW
GP
MB
WL
Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 14 - Sep - 2022